Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOtorhinolaryngology (ENT)BCBS Rhode Island Cochlear Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

    Cochlear Implants

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts

    Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy addresses medical necessity, coverage, prior authorization, and coding for cochlear implantation and related component replacement or upgrades for Medicare Advantage Plans and Commercial Products.

    Policy Summary
    PayerBlue Cross Blue Shield - Rhode Island
    PolicyCochlear Implants
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateSep 1, 2026
    Last ReviewMay 6, 2026
    Next Review DateN/A
    Key ActionFor Commercial Products, providers should obtain prior authorization through the online tool for CPT 69930 requests effective September 1, 2026.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Product categories addressed
    ≤60%Medicare Advantage hearing recognition threshold
    69930Cochlear device implantation CPT code
    Q0/Q1Clinical-trial modifiers

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Medical Necessity and Coverage Criteria

    Cochlear implantation — bilateral hearing loss

    Unilateral or bilateral implantation may be medically necessary when all applicable criteria are met.

    Bilateral hearing loss cochlear implantation: The patient has bilateral moderate-to-profound pre- or post-lingual sensorineural hearing loss, the cochlear implant device is FDA-approved, and the patient has shown limited or no benefit from hearing aids.

    Applies to standard cochlear implantation.

    Hybrid cochlear implant/hearing aid

    Hybrid implantation may be medically necessary when all applicable criteria are met.

    Hybrid cochlear implant/hearing aid: The patient has bilateral moderate-to-profound high-frequency sensorineural hearing loss with residual low-frequency hearing sensitivity and receives limited benefit from appropriately fitted bilateral hearing aids. The device includes a hearing aid integrated into the cochlear implant’s external sound processor.

    An example is the Nucleus Hybrid L24 Cochlear Implant System.

    Medicare Advantage cochlear implantation

    Medicare Advantage cochlear implantation may be used when all criteria are met.

    Medicare Advantage clinical criteria: The patient has bilateral pre- or post-linguistic sensorineural moderate-to-profound hearing loss; demonstrates limited benefit from appropriate hearing or vibrotactile aids; has the cognitive ability to use auditory clues; is willing to undergo an extended rehabilitation program; has no middle-ear infection; has an accessible cochlear lumen structurally suited to implantation; has no lesions in the auditory nerve or acoustic areas of the central nervous system; has no contraindications to surgery; and the device will be used in accordance with FDA-approved labeling.Best-aided recorded open-set sentence recognition ≤60% correct

    CMS may provide coverage outside these criteria when the procedure is performed in an FDA-approved Category B investigational device exemption clinical trial or as a routine cost in a qualifying clinical trial.

    Commercial Products — CPT 69930

    For Commercial Products, CPT 69930 may be considered medically necessary when the online authorization criteria are met.

    Commercial Products: CPT 69930, cochlear device implantation with or without mastoidectomy, is medically necessary only when the medical criteria in the online authorization tool for participating providers are met.

    Replacement of cochlear implant components

    Replacement of internal or external components may be medically necessary when either qualifying condition is present.

    Necessary component replacement

    • The existing component has an inadequate response that interferes with the individual’s activities of daily living.
    • The component is no longer functional and cannot be repaired.

    Unilateral hearing loss

    Unilateral hearing-loss implantation may be covered only in qualifying clinical-trial circumstances.

    Qualifying clinical-trial pathway

    • Cochlear implantation for unilateral hearing loss, with or without tinnitus, is performed as part of an FDA-approved Category B investigational device exemption clinical trial.
    • Cochlear implantation for unilateral hearing loss, with or without tinnitus, is provided as a routine cost in a clinical trial.

    Commercial Products — online authorization medical criteria

    Considered medically necessary when the medical criteria in the online authorization tool are met.

    Online authorization medical criteria: The medical criteria in the online authorization tool must be met.

    Detailed criteria are not reproduced in this policy document.

    Upgrades of an existing, functioning external system for aesthetic improvement or convenience are not covered. This includes smaller-profile components or changing from a body-worn external sound processor to a behind-the-ear (BTE) model.

    Replacement of internal or external cochlear implant components solely to obtain advanced technology or a next-generation device is not covered because the replacement is considered a convenience upgrade.

    Coding and Billing Guidance

    Medicare Advantage Plans — Covered CPT CodeCPTCovered
    69930Cochlear device implantation, with or without mastoidectomy
    Commercial Products — CPT Code That May Be Medically NecessaryCPTCovered
    69930Cochlear device implantation, with or without mastoidectomy
    Medicare Advantage Plans — Investigational Clinical-Trial ModifierModifier
    Q0Investigational clinical service provided in a clinical research study that is in an approved clinical research study
    Medicare Advantage Plans — Routine Clinical-Trial ModifierModifier
    Q1Routine clinical service provided in a clinical research study that is in an approved clinical research study
    Potentially Medically Necessary CPT Code — Commercial ProductsCPTCovered
    69930Cochlear device implantation, with or without mastoidectomy
    Best-aided open-set sentence recognition
    TestRecorded tests of open-set sentence recognition
    Listening conditionBest-aided listening condition
    ThresholdLess than or equal to 60% correct

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Commercial Prior Authorization

    For Commercial Products, prior authorization is recommended through the online authorization tool for participating providers effective September 1, 2026.

    • Applies to participating providers.
    • Use the online tool for Commercial Products requests.
    Prior Authorization

    Commercial Medical-Criteria Review

    For Commercial Products, requests for CPT 69930 are evaluated through the online authorization tool. The code may be considered medically necessary when the applicable online medical criteria are met.

    • CPT 69930 — Cochlear device implantation, with or without mastoidectomy.
    • Effective September 1, 2026.

    Unsupported block type: documentation

    Documentation Required

    Medicare Advantage Clinical Eligibility

    For Medicare Advantage Plans, document bilateral moderate-to-profound pre- or post-linguistic sensorineural hearing loss and limited benefit from amplification, along with the clinical and surgical factors supporting implantation.

    • Limited amplification benefit: test scores of ≤60% correct in the best-aided listening condition on recorded open-set sentence-recognition tests.
    • Document cognitive ability to use auditory clues and willingness to complete extended rehabilitation.
    • Document freedom from middle-ear infection, an accessible cochlear lumen structurally suited to implantation, no relevant auditory-nerve or central-nervous-system lesions, and no contraindications to surgery.
    • Confirm use consistent with FDA-approved labeling.
    Documentation Required

    Hearing-Aid Benefit Documentation

    Document the hearing-loss pattern and the member’s limited benefit from appropriately fitted hearing aids when supporting cochlear implantation or a hybrid cochlear implant/hearing-aid device.

    • Bilateral implantation: bilateral moderate-to-profound pre- or post-lingual sensorineural hearing loss with limited or no benefit from hearing aids.
    • Hybrid device: bilateral moderate-to-profound high-frequency sensorineural hearing loss with residual low-frequency hearing sensitivity and limited benefit from appropriately fitted bilateral hearing aids.
    Denial Risk

    Convenience or Technology Upgrades

    Upgrading an existing, functioning external system solely for convenience, aesthetics, a smaller profile, a behind-the-ear configuration, advanced technology, or a next-generation device is not covered.

    • Examples include changing from a body-worn external sound processor to a behind-the-ear model.
    • Technology upgrades are not covered when the existing system is functioning.
    Denial Risk

    Replacement Requires Functional Necessity

    Replacement of internal or external components is not supported solely because a newer system is available. Replacement is medically necessary only when the existing component is no longer functional and cannot be repaired, or when its inadequate response interferes with activities of daily living.

    • Document the component’s functional status and repairability.
    • Document inadequate response and interference with activities of daily living when applicable.
    Denial Risk

    Unilateral Hearing Loss Coverage Limits

    Cochlear implantation for unilateral hearing loss, with or without tinnitus, is not routinely covered outside qualifying clinical-trial pathways.

    • Coverage may be available as part of an FDA-approved Category B investigational device exemption clinical trial.
    • Routine clinical-trial costs may be covered when applicable.
    Prior Authorization

    CPT 69930 Criteria Requirement

    Commercial Products requests billed with CPT 69930 require satisfaction of the medical criteria in the online authorization tool before the service may be considered medically necessary.

    • CPT 69930 — Cochlear device implantation, with or without mastoidectomy.
    • The criteria apply when submitting the request through the online tool.
    Denial Risk

    Failure to Meet Online Criteria

    For Commercial Products, cochlear implantation may not be considered medically necessary when the applicable medical criteria in the online authorization tool are not met.

    • Failure to meet the online criteria creates a denial risk.
    • Submit documentation addressing all applicable clinical requirements.

    Clinical Background

    A cochlear implant is an electronic prosthetic device that provides direct electrical stimulation to auditory nerve fibers for individuals with severe-to-profound hearing loss who receive limited benefit from hearing aids. External components capture, process, and transmit sound to an implanted receiver and electrode array, which stimulate the auditory nerve.

    Key Definitions

    Limited benefit from amplification
    DefinitionLimited benefit from amplification is demonstrated by a score of 60% or less in the best-aided listening condition on recorded tests of open-set sentence recognition.
    Applicable aidsAppropriate hearing or vibrotactile aids
    Population describedIndividuals with bilateral pre- or post-linguistic, sensorineural, moderate-to-profound hearing loss
    Cochlear implant components
    Internal receiverImplanted within the temporal bone
    Electrode arrayExtends from the receiver into the cochlea through a surgically created opening in the round window of the middle ear
    External componentsMicrophone, external sound processor, and external transmitter
    Policy Summary
    PayerBlue Cross Blue Shield - Rhode Island
    PolicyCochlear Implants
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateSep 1, 2026
    Last ReviewMay 6, 2026
    Next Review DateN/A
    Key ActionFor Commercial Products, providers should obtain prior authorization through the online tool for CPT 69930 requests effective September 1, 2026.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaCoding and Billing GuidanceAuthorization, Documentation, and Denial RisksClinical BackgroundKey Definitions